PDX INSIGHTS
PIONEERING CANCER RESEARCH
Home
Collections
Bladder
Breast
Leukemia
Liver - Pediatric
Pancreas
Sarcoma
Omics Tools
Management
Data Management
File Management
Drug Studies
Contact Us
Log In
You need to enable JavaScript to run this app page.
Breast
HCI-025
Model Details
Patient
PDX Model
Drug Studies
Histology
Metastasis
Patient Treatment
Patient Information for Model: HCI-025
Contact Model Developer
Model Contact
Model: HCI-025
Model Contact: Alana Welm
Institution: HCI Breast PDX Program
Email:
Alana.Welm@hci.utah.edu
Patient Information
Clinical Timeline
Color Keys:
Positive
Negative
N/A
Clinical Information at Collection
Clinical Biomarkers/Mutations at Collection
Pathology Information at Collection
Model Information for Model: HCI-025
Model Details - Initial Implantation of Patient Tissue
Biomarkers & Mutations
Model Details - Acceptable Conditions for Passaging
Mutations (Cancer Gene Census List)
Mutation data is currently not available.
CNV
There are no omics data for this model.
Drug Studies for Model: HCI-025
Treatment Response Across All Studies
CR <=-95% to -100%
PR <-30% to >-95%
SD >=-30% to +20%
PD >=+20%
NA
Drug Study: Legacy2017
Study Metadata
Study ID:
Legacy2017
Study Type:
Efficacy
Study Description:
Dosing Initiation Timepoint:
Number of Arms:
16
Mouse Strain:
PI:
Alana Welm
Study Title:
Legacy 2017 - PDX Efficacy Study
Treatments:
5-Fluorouracil, MK-1775, Olaparib, Ponatinib, Doxorubicin, AZD8186, Palbociclib, TAK228, Palbociclib+AZD8186, Palbociclib+TAK228, Apitilosib, Everolimus, Gemcitabine, Paclitaxel, Lapatinib
Study Duration:
Transplant Site
Transplant Material:
Study Design
Total arms showing: 3
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Study Description
Arm Type
Treatment Arms
Number of Mice
Dose (mg/kg)
Concentration (mg/ml)
Vehicle
Route
Dosing Schedule
Treatment
Apitilosib
3
1
Control
Vehicle
4
Treatment
Everolimus
4
5
Total arms showing: 3
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Treatment Results
Total treatment results showing: 3
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Treatment Arm
Treatment Duration
Monitoring Method
Monitor Duration
Tumor volume over time (%)
Response Category
Apitilosib
43
-40
PR
Vehicle
43
207
PD
Everolimus
43
-53
PR
Total treatment results showing: 3
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Histology Information for Model: HCI-025
There are no histology images for this model.
Metastasis Information for Model: HCI-025
Patient
PDX
Abdomen
Adrenal gland
Bone
Bone (de novo)
Bones
Brain
CTC
Chest
Chest wall
Contralateral Breast
Dura
Fallopian Tubes
Head
Kidney
LMD
Liver
Lung
Lymph node
Lymph nodes
Neck
None
Ovary
Pancreas
Pericardium
Peritoneal cavity
Peritoneum
Pleura
Pleural effusion
Shoulder
Skin
Spine
Spleen
Thoracic Spine
Thymus
medistinal and right hilar
Patient Treatment Information for Model: HCI-025
Event Id
Treatment
Treatment Setting
Age at Start
Age at End
Duration
Clinical Response
11
Adriamycin/Cyclophosphamide, Paclitaxel
Neoadjuvant
38.08
38.33
91 days
12
Radiaton Therapy
Neoadjuvant
38.41
38.83
153 days
Progressive disease
15
Gemzar with Carboplating added
Neoadjuvant
40.33
40.5
62 days
Progressive disease
16
Xeloda
Neoadjuvant
40.67
40.83
58 days
Progressive disease
17
Paclitaxel
Neoadjuvant
40.83
40.91
29 days
Progressive disease
18
Navelbine
Neoadjuvant
40.91
41.0
33 days
Progressive disease
21
Doxil
Adjuvant
41.0
41.08
29 days
Progressive disease
22
Novartis PDR001x2101 trial
Adjuvant
41.16
41.33
62 days
Progressive disease
Please wait...
